Pfizer invests $25 million in Vedanta Biosciences

12 January 2021
vedanta-big

USA-based microbiome company Vedanta Biosciences today announced that pharma giant Pfizer (NYSE: PFE) has made a $25 million investment in the company, as part of the Pfizer Breakthrough Growth Initiative.

Vedanta, an affiliate of London-listed PureTech Health (LSE: PRTC), intends to use the proceeds to fund a Phase II study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021. Top-line Phase I study data showed VE202 was generally safe and well-tolerated at all doses and demonstrated durable and dose-dependent colonization.

“We thank Pfizer for its investment in Vedanta and support of our IBD program and look forward to advancing microbiome modulation as a potential new treatment modality for IBD patients,” said Bernat Olle, co-founder and chief executive of Vedanta Biosciences.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology